Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment

“Investigating liso-cel even earlier, besides just waiting for the patients to relapse, and then give it to them makes a lot of sense. But I feel it absolutely needs to be tested with scientific rigor within a clinical trial setting. There is some data that's emerging where we could bring liso-cel if interim PET scans are partial response or stable disease. And I think that may be the next opportunity to showcase the strength of liso-cel in terms of bringing it to earlier line settings.”

Lisocabtagene maraleucel (liso-cel) has continued to demonstrate deep responses in patients with primary refractory/relapsed (r/r) large B-cell lymphoma (LBCL) and superiority over standard of care. The therapy is approved under the name Breyanzi for patients with r/r LBCL based off of data from the phase 3 TRANSFORM (NCT03575351) and TRANSCEND trials (NCT02631044).

Updated, 3-year data from TRANSFORM were presented by Manali Kamdar, MD, associate professor of medicine – hematology, University of Colorado School of Medicine - Anschutz Medical Campus, and UCHealth Blood Disorders and Cell Therapies Center at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois. CGTLive® spoke with Kamdar to learn more about moving liso-cel and other chimeric antigen receptor (CAR) T-cell therapies to earlier lines of therapy.

Click here to view more coverage from the 2024 ASCO meeting.

REFERENCE

Kamdar MK, Solomon SR, Arnason J, et al. Lisocabtagenemaraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7013